KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Chen et al. have also comprehensively characterized the NK cell compartment in CML patients under imatinib therapy and showed that the expression of activating NK cell receptor NKG2D was significantly decreased with imatinib therapy [66].